Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2425191 | 0.78 | MAPK9 (0.51) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL7896074 | 0.78 | MAPK9 (0.48) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3480233 | 0.77 | MAPK9 (0.55) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL2419827 | 0.77 | MAPK9 (0.57) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3479929 | 0.76 | DRD2 (0.60) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL2423054 | 0.76 | MAPK9 (0.59) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL3479828 | 0.76 | MAPK9 (0.52) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL6431934 | 0.76 | MAPK9 (0.47) | MAPK9MAPK10MEN1KMT2ALMNA | |
| SCHEMBL2425741 | 0.75 | MAPK9 (0.59) | MAPK9MAPK10MEN1KMT2AALDH1A1 | |
| SCHEMBL7894679 | 0.74 | MAPK9 (0.54) | MAPK9MAPK10MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | claimed |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | APPLIED RESERACH SYSTEMS ARS HOLDING N.V. (AN) | 2007-02-22 | — | — | US | claimed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | claimed |
| US-8658640-B2 | JNK inhibitors for the treatment of endometriosis | MERCK SERONO SA (CH) | 2014-02-25 | — | — | US | disclosed |
| US-8592414-B2 | JNK inhibitors for the treatment of endometriosis | Merck Serono, S.A. (CH) | 2013-11-26 | — | — | US | disclosed |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-24 | — | — | US | disclosed |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | LABORATOIRES SERONO S.A. (CH) | 2013-10-10 | — | — | US | disclosed |
| US-7705052-B2 | Sulfonamide derivatives for the treatment of diabetes | MERCK SERONO SA (CH) | 2010-04-27 | — | — | US | disclosed |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | LABORATORIES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | LABORATOIRES SERONO SA (CH) | 2009-07-09 | — | — | US | disclosed |
| EP-2026802-A2 | JNK INHIBITORS FOR TREATMENT OF SKIN DISEASES | Laboratoires Serono SA (CH) | 2009-02-25 | — | — | EP | disclosed |
| EP-1904181-A2 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETREOSIS | LABORATOIRES SERONO S.A. (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2008-02-14 | — | — | US | disclosed |
| WO-2007141224-A2 | JNK INHIBITORS FOR TREATMENT OF SKIN DISEASES | LABORATOIRES SERONO SA (CH) | 2007-12-13 | — | — | WO | disclosed |
| WO-2007011762-A2 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETREOSIS | LABORATOIRES SERONO S.A. (CH) | 2007-01-25 | — | — | WO | disclosed |
| EP-1218374-B1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS (AN) | 2005-11-16 | — | — | EP | disclosed |
| EP-1218374-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001023378-A1 | PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176762-A1 | JNK Inhibitors for Treatment of Skin Diseases | MAPKAPK2, JUN, MAP3K13 | MAPK9 33/4885MAPK10 35/4885MEN1 4590/4885 |
| US-20070043027-A1 | Sulfonamide derivatives for the treatment of diabetes | CBR3, INSR, CS | MAPK9 2768/4885MAPK10 1940/4885MEN1 3205/4885 |
| US-20080039377-A1 | Composition Comprising a Jnk Inhibitor and Cyclosporin | LCK, MAPKAPK2, MAP3K20 | MAPK9 36/4885MAPK10 40/4885MEN1 1582/4885 |
| US-20130281447-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPK9 49/4885MAPK10 40/4885MEN1 3898/4885 |
| US-20090176761-A1 | JNK Inhivitors for the Treatment of Endometriosis | MAPKAPK2, MAP3K20, MAP3K6 | MAPK9 35/4885MAPK10 26/4885MEN1 4390/4885 |
| US-20130267512-A1 | JNK INHIBITORS FOR THE TREATMENT OF ENDOMETRIOSIS | MAPKAPK2, MAPKAPK3, JUN | MAPK9 49/4885MAPK10 40/4885MEN1 3898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.